Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label comparison of tacrolimus formulations and cyclosporin in kidney transplant recipients
2015-003288-12Phase 3
- Sponsor
- Fujisawa Pharmaceutical
- Start
- Aug 2015
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus and cyclosporine in kidney allograft rejection and Kidney transplant recipient care (3 arms), sponsored by Fujisawa Pharmaceutical. Primary endpoint: Efficacy failure rate.
02
Drugs
tacrolimuscyclosporine
03
Conditions
kidney allograft rejectionKidney transplant recipient care
Beyond the preview
Go deeper on 2015-003288-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003288-12.